REG - Trellus Health PLC - Grant of Share Options

Trellus HealthAnnouncement

23/04/2025 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250423:nRSW9058Fa&default-theme=true

RNS Number : 9058F  Trellus Health PLC  23 April 2025

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Grant of Share Options

 

LONDON, U.K. AND NEW YORK, U.S. (23 April 2025). Trellus Health® plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate®, a digital platform
that integrates data analytics with personalised, scientifically proven
resilience programs and value-based solutions to manage complex chronic
conditions, announces that the Board has granted options over a total of
1,000,000 ordinary shares of £0.0006 each in the capital of the Company (the
"Share Options") to the following PDMRs:

 

 Name            Position                                Options granted  Total Options Held Post Issue

 Marla Dubinsky  Chief Executive Officer                 500,000          1,000,000
 Joy Bessenger   Chief Financial Officer (non-Director)  500,000          2,000,000

 

 

The Share Options, which have been issued in line with the Company's existing
share option plan, have an exercise price of 14p per ordinary share.

 

The Share Options vest and become exercisable as to one third in 12 months of
the grant date and in eight (8) equal quarterly instalments thereafter, of
which the first instalment shall vest three months after the first anniversary
of the grant date and the eighth shall vest 36 months after the grant date

 

 

For further information please contact:

 

 Trellus Health plc                                                  https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder          Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets (Nominated Adviser and Broker)               Tel: +44 (0)20 7496 3000
 Jen Boorer / James Todd / Jalini Kalaravy

 Walbrook PR                         Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                     (mailto:trellus@walbrookpr.com)
 Paul McManus / Lianne Applegarth /  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/

 Alice Woodings                      +44 (0)7407 804 654

 

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer
hospitalisations and a reduction of over 70% in emergency room visits. Given
the common emotional and mental health struggles associated with a variety of
chronic conditions, Trellus Health considers its approach to have potential
utility and demand across many conditions.

 

Trellus Health also offers a seamless solution for pharmaceutical partners
from clinical trials to commercialisation, harnessing resilience-based methods
to drive both trial and patient support success by empowering patients to stay
engaged, adhere to their treatment, and manage their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both world-leading experts at treating and healing
both the physical and emotional impacts of IBD and have been innovators for
whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Marla Dubinsky

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer (Director)

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Trellus Health plc

 b)   LEI                                                          2138002FHWJSR8YKP295

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Options over ordinary shares of £0.0006 each in the Company

      Identification code                                          GB00BNNFM402

 b)   Nature of the transaction                                    Grant of options over shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)               Volume(s)
                                                                                     £0.14 exercise price   500,000

 d)   Aggregated information

      - Aggregated volume                                          N/A

      - Price                                                      N/A

 e)   Date of the transaction                                      23 April 2025

 f)   Place of the transaction                                     Outside of trading venue - off market

 

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Joy Bessenger

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer (Not a director)

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Trellus Health plc

 b)   LEI                                                          2138002FHWJSR8YKP295

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Options over ordinary shares of £0.0006 each in the Company

      Identification code                                          GB00BNNFM402

 b)   Nature of the transaction                                    Grant of options over shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)               Volume(s)
                                                                                     £0.14 exercise price   500,000

 d)   Aggregated information

      - Aggregated volume                                          N/A

      - Price                                                      N/A

 e)   Date of the transaction                                      23 April 2025

 f)   Place of the transaction                                     Outside of trading venue - off market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHIJMJTMTTTBLA